BUENA, N.J., Jan. 11, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the 34th Annual J.P. Morgan Healthcare Conference. The Conference will take place on January 11-14, 2016 at the Westin St. Francis Hotel in San Francisco, California.
Jason Grenfell-Gardner, President and CEO and Jenniffer Collins, Chief Financial Officer of Teligent, Inc. will present on Thursday, January 14, 2016 at 10:30 a.m. PT.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 90 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
Forward-Looking Statements
This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in Teligent, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
|
Contact: |
Jenniffer Collins |
|
Teligent, Inc. | |
|
(856) 697-4379 | |
Logo - http://photos.prnewswire.com/prnh/20151113/287129LOGO
SOURCE Teligent, Inc.